12/19
01:32 pm
chrs
Yahoo Finance [Yahoo! Finance]
Low
Report
Yahoo Finance [Yahoo! Finance]
12/18
08:38 am
chrs
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 [Yahoo! Finance]
Medium
Report
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 [Yahoo! Finance]
12/18
08:30 am
chrs
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Medium
Report
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
12/18
08:14 am
chrs
Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases [Yahoo! Finance]
Medium
Report
Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases [Yahoo! Finance]
12/5
08:28 am
chrs
Coherus BioSciences, Inc. (NASDAQ: CHRS) had its price target raised by analysts at Robert W. Baird from $4.00 to $6.00. They now have an "outperform" rating on the stock.
High
Report
Coherus BioSciences, Inc. (NASDAQ: CHRS) had its price target raised by analysts at Robert W. Baird from $4.00 to $6.00. They now have an "outperform" rating on the stock.
12/4
08:09 am
chrs
Coherus BioSciences, Inc. (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Low
Report
Coherus BioSciences, Inc. (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
12/3
07:42 am
chrs
Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth [Yahoo! Finance]
Medium
Report
Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth [Yahoo! Finance]
12/3
07:18 am
chrs
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. [Yahoo! Finance]
Low
Report
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. [Yahoo! Finance]
12/3
07:00 am
chrs
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
High
Report
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
11/27
04:01 pm
chrs
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
Medium
Report
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
11/7
08:36 am
chrs
Coherus BioSciences, Inc. (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Coherus BioSciences, Inc. (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
11/7
02:31 am
chrs
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... [Yahoo! Finance]
Medium
Report
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... [Yahoo! Finance]
11/6
07:28 pm
chrs
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Medium
Report
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/6
04:13 pm
chrs
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
11/6
04:01 pm
chrs
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
11/5
08:22 am
chrs
Coherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to Know Ahead of Earnings [Yahoo! Finance]
Medium
Report
Coherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to Know Ahead of Earnings [Yahoo! Finance]
10/30
04:20 pm
chrs
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
Low
Report
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
10/19
02:07 am
chrs
Coherus BioSciences, Inc. (NASDAQ: CHRS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Coherus BioSciences, Inc. (NASDAQ: CHRS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
10/11
11:09 pm
chrs
Coherus BioSciences, Inc. (NASDAQ: CHRS) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Medium
Report
Coherus BioSciences, Inc. (NASDAQ: CHRS) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.